Katie is Managing Director at the JDRF T1D Fund, an evergreen, Boston-based venture philanthropy fund launched in 2017, focused on accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D) through catalytic equity investments. She currently serves on the board of Fund portfolio companies DiogenX, Veralox, i2O, Capillary Bio, Biolinq, Seraxis. Enthera, GentiBio and has previously served on the board of T1D Fund companies Pandion (sold to Merck), Protomer (sold to Eli Lilly), and Inversago.
Katie has been a life-sciences and medical device-oriented venture capital investor in the US and Europe for over a decade, previously with Endeavour Vision, a Geneva-based growth stage venture fund, investing in medical devices and digital health companies, and at Sofinnova Partners, Paris, a leading early-stage life sciences fund, investing in medical technologies. In her prior roles she served on several medical device company boards including of ReCor Medical (sold to Otsuka Holdings), Shockwave Medical (NASDAQ: SWAV), and RefleXion Medical.
Prior to VC, Katie held roles in Business Development, Sales and Marketing at Medtronic in the Cardiac and Vascular businesses both in the US and in Europe. She began her career at McKinsey & Company and Partners Healthcare in Boston. Katie holds a M.B.A. in Healthcare Management from the Wharton School at the University of Pennsylvania and a B.A. cum laude in International Relations and Political Science from Yale University.
Katie and her husband live in Cambridge, MA with their four children.